Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
If approved, DTX401 would be the first treatment to address the disease at its root cause
Nadda underlined that India’s policy framework is aligned with this transformation
Subscribe To Our Newsletter & Stay Updated
